Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

Abstract Background Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable...

Full description

Bibliographic Details
Main Authors: In Hee Lee, Soo Jung Lee, Jeeyeon Lee, Jin Hyang Jung, Ho Yong Park, Shin Young Jeong, Sang-woo Lee, Yee Soo Chae
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Cancer
Subjects:
Breast cancer
Neoadjuvant chemotherapy
Pathologic complete response
SUVmax
Online Access:http://link.springer.com/article/10.1186/s12885-020-07505-w

Internet

http://link.springer.com/article/10.1186/s12885-020-07505-w

Similar Items